Derivative

ION-owned LIST upgrades FastTrade solution, successfully migrates clients onto Euronext's Optiq trading platform

Retrieved on: 
Wednesday, April 19, 2023
Millennium, Risk management, Acquisition, Borsa Italiana, Derivative, OMS, ION, Professional, Security (finance), Euronext

MILAN, April 19, 2023 /PRNewswire/ -- LIST , an ION company, has successfully updated its award-winning market making and trading FastTrade solution, facilitating the migration of Borsa Italiana trading clients onto Euronext's Optiq technology trading platform.

Key Points: 
  • MILAN, April 19, 2023 /PRNewswire/ -- LIST , an ION company, has successfully updated its award-winning market making and trading FastTrade solution, facilitating the migration of Borsa Italiana trading clients onto Euronext's Optiq technology trading platform.
  • Euronext , the pan-European stock exchange and market infrastructure, is replacing the Borsa Italiana exchange's previous Millennium technology with its cutting-edge Optiq trading platform.
  • LIST's upgraded FastTrade solution is fully customizable and offers advanced trading functionalities specific to Euronext's Optiq technology trading platform.
  • To ensure clients migrated successfully, LIST activated new data centers, communication lines, and software versions to support changes in market models and workflows.

ION-owned LIST upgrades FastTrade solution, successfully migrates clients onto Euronext's Optiq trading platform

Retrieved on: 
Wednesday, April 19, 2023
Millennium, Risk management, Acquisition, Borsa Italiana, Derivative, OMS, ION, Professional, Security (finance), Euronext

MILAN, April 19, 2023 /PRNewswire/ -- LIST , an ION company, has successfully updated its award-winning market making and trading FastTrade solution, facilitating the migration of Borsa Italiana trading clients onto Euronext's Optiq technology trading platform.

Key Points: 
  • MILAN, April 19, 2023 /PRNewswire/ -- LIST , an ION company, has successfully updated its award-winning market making and trading FastTrade solution, facilitating the migration of Borsa Italiana trading clients onto Euronext's Optiq technology trading platform.
  • Euronext , the pan-European stock exchange and market infrastructure, is replacing the Borsa Italiana exchange's previous Millennium technology with its cutting-edge Optiq trading platform.
  • LIST's upgraded FastTrade solution is fully customizable and offers advanced trading functionalities specific to Euronext's Optiq technology trading platform.
  • To ensure clients migrated successfully, LIST activated new data centers, communication lines, and software versions to support changes in market models and workflows.

The Simply Good Foods Company Reports Second Quarter 2023 Financial Results and Updates Full Fiscal Year 2023 Outlook

Retrieved on: 
Wednesday, April 5, 2023
Tax, Advertising, Bellisio Foods, International, Interest, Marketing, Debt, The Good Food Institute, Accounting standard, G&A, GAAP, Earnings per share, IRI, Derivative, Internet, EBITDA, Investment, Depreciation, Convenience, Growth, EPS, Atkins, Health, Adjustment, Total, Bookkeeping, Coal, Pharmaceutical industry, Fast food, Security (finance), Publishing, Video game, Bank, Quest

In the second quarter of fiscal year 2023, total Simply Good Foods combined measured and unmeasured channel U.S. retail takeaway increased about 16%.

Key Points: 
  • In the second quarter of fiscal year 2023, total Simply Good Foods combined measured and unmeasured channel U.S. retail takeaway increased about 16%.
  • In the second quarter of fiscal 2022, Diluted EPS reflects the remeasurement of private warrant liabilities which did not repeat in the second quarter of fiscal 2023.
  • Year-to-Date Second Quarter 2023 Highlights vs. Year-to-Date Second Quarter 2022
    Net sales increased $19.5 million, or 3.4%, to $597.5 million.
  • For the year-to-date second quarter fiscal 2023, the Company reported Diluted EPS of $0.61 versus $0.40 in the year ago period.

ABB Ltd: ABB launches new share buyback program of up to $1 billion

Retrieved on: 
Friday, March 31, 2023
Treasury, SIX Swiss Exchange, Annual general meeting, ABB, Share repurchase, Engineering, ISIN, Derivative, Automation, Software, Renewable energy, Cryptocurrency, EU

On April 3, 2023, ABB will launch its previously announced new share buyback program of up to $1 billion.

Key Points: 
  • On April 3, 2023, ABB will launch its previously announced new share buyback program of up to $1 billion.
  • Since July 2020, ABB has repurchased about 286 million shares for capital reduction purposes for a total amount of approximately $8.6 billion.
  • This includes 82,742,500 shares that were repurchased under the share buyback programs 2021/22 and 2022/23 and remain to be cancelled.
  • The new share buyback program will be managed by a bank mandated by ABB that, based on trading parameters received from ABB, will make its trading decisions concerning the timing of share repurchases independently of ABB.

ESMA issues Statement on the Derivatives Trading Obligation

Retrieved on: 
Thursday, March 30, 2023
CFTC, European Securities and Markets Authority, ICE, Public, ICE Clear Credit, FCA, Derivative, Commodity Futures Trading Commission, ESMA, UK, Security (finance)

ESMA issues Statement on the Derivatives Trading Obligation

Key Points: 
  • ESMA issues Statement on the Derivatives Trading Obligation
    The European Securities and Markets Authority (ESMA), the EU’s financial markets regulator and supervisor, has today published a Public Statement on the DTO in the context of the migration of credit default swap contracts out of ICE Clear Europe.
  • The objective of this statement is to support the orderly migration of positions from ICE Clear Europe to other CCPs, following the announcement of the forthcoming closure of ICE Clear Europe’s credit default swap clearing service on 27 October 2023.
  • Considering the global dimension of the migration, ESMA has closely coordinated its approach with the UK Financial Conduct Authority (FCA) and the US Commodity Futures Trading Commission (CFTC).
  • Further information:
    Sarah Edwards
    Senior Communications Officer
    @ Email: [email protected]

Zscaler Reports Second Quarter Fiscal 2023 Financial Results

Retrieved on: 
Thursday, March 2, 2023
Zoom Video Communications, GAAP, Classification, High, Software as a service, Architecture, ZS, Research, ASU, AA, Private sector, Canonical, Joint, Organization, SAN, Tax, Political moderate, Derivative, Government agency, Investment, Conversion, Treasury, FedRAMP, Growth, Federation, SSE, ESG, Cryptocurrency, Video game, Bank, Security (finance), Beauty salon, MSCI

SAN JOSE, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Zscaler, Inc. (Nasdaq: ZS), the leader in cloud security, today announced financial results for its second quarter of fiscal year 2023, ended January 31, 2023.

Key Points: 
  • SAN JOSE, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Zscaler, Inc. (Nasdaq: ZS), the leader in cloud security, today announced financial results for its second quarter of fiscal year 2023, ended January 31, 2023.
  • Non-GAAP net income per share was $0.37, compared to $0.13 in the second quarter of fiscal 2022.
  • Effective August 1, 2022, the beginning of our fiscal year ending July 31, 2023, we adopted Accounting Standards Update No.
  • Zscaler will host a conference call for analysts and investors to discuss its second quarter of fiscal 2023 and outlook for its third quarter of fiscal 2023 and full year fiscal 2023 today at 1:30 p.m. Pacific time (4:30 p.m. Eastern time).

Terran Biosciences announces publication of PCT patent application covering novel orally active forms of psilocin with improved pharmacokinetic properties

Retrieved on: 
Friday, February 24, 2023
Psilocybin, Terran, Prodrug, Therapy, Patent, Patient, Brain, PCT, Human, Derivative, Depression, Pharmacokinetics, Pharmaceutical industry

NEW YORK, Feb. 24, 2023 /PRNewswire/ -- Terran Biosciences ("Terran"), a biotech platform company dedicated to the development of transformational therapeutics for neurological and psychiatric diseases, has announced the publication of a PCT patent application covering novel prodrugs of psilocin.

Key Points: 
  • NEW YORK, Feb. 24, 2023 /PRNewswire/ -- Terran Biosciences ("Terran"), a biotech platform company dedicated to the development of transformational therapeutics for neurological and psychiatric diseases, has announced the publication of a PCT patent application covering novel prodrugs of psilocin.
  • Psilocin and psilocybin are both active compounds in psychedelic mushrooms, and psilocybin is the most well-studied prodrug of psilocin.
  • Terran has designed novel, faster-acting prodrugs of psilocin that demonstrate a shorter duration of activity compared to psilocybin in animal studies.
  • With new data from animal models published in this PCT patent application, Terran believes these prodrugs may represent the most comprehensive examples of improved prodrugs of psilocin compared to psilocybin.

ChromaDex Announces Issuance of New U.S. Patent on Dihydronicotinamide Riboside (NRH) and Dihydronicotinic Acid Riboside (NARH), Further Solidifying ChromaDex as the Leader in the Nicotinamide Adenine Dinucleotide (NAD+) Precursor Space

Retrieved on: 
Wednesday, February 22, 2023
Biotechnology, Health, Patent Law, Professional Services, Pharmaceutical, NAD, Biochemistry, Mayo Clinic, Metabolism, Derivative, Ageing, ChromaDex, United States patent law, Journal, Frontiers, Patent, NAR, NRH, Molecular Metabolism, Attention, Macrophage, NADH, Pharmaceutical industry, Immunology

Niagen® is the sole active ingredient in ChromaDex’s flagship consumer product, Tru Niagen®, the most efficient and well-studied NAD+ precursor currently in the market.

Key Points: 
  • Niagen® is the sole active ingredient in ChromaDex’s flagship consumer product, Tru Niagen®, the most efficient and well-studied NAD+ precursor currently in the market.
  • “There is a great deal of interest in the scientific community around NRH,” said Rob Fried, CEO of ChromaDex.
  • The composition claims that have been granted are amongst the strongest patent claims that can be achieved for this NAD+ precursor.
  • U.S. Patent 11,584,770 is part of the patent family titled “Methods of Preparing Nicotinamide Riboside and Derivatives Thereof” exclusively licensed from Queen’s University Belfast.

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Results

Retrieved on: 
Thursday, February 16, 2023
Research, FDA, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, New Drug Application, Trial of the century, Shanda, Test Claimants in the Franked Investment Income Group Litigation v IRC, Constipation, PDUFA, Safety, Expense, EBITDA, Patient, GAAP, Liver, Total, Interstitial cystitis, Conversion, Primary biliary cholangitis, Autoimmune disease, Phase, Interest, PBC, Share repurchase, Functional constipation, Derivative, Endometriosis, Depreciation, AbbVie, Asus, Ageing, Pharmaceutical industry, Video game, Security (finance), Cryptocurrency, Life insurance, Reinsurance, Bookkeeping, IC/BPS, Ironwood

Total revenues in the fourth quarter of 2022 were $107.2 million, compared to $117.1 million in the fourth quarter of 2021.

Key Points: 
  • Total revenues in the fourth quarter of 2022 were $107.2 million, compared to $117.1 million in the fourth quarter of 2021.
  • Operating expenses in the fourth quarter of 2022 were $38.8 million, compared to $60.5 million in the fourth quarter of 2021.
  • Adjusted EBITDA was $68.7 million in the fourth quarter of 2022, compared to $57.0 million in the fourth quarter of 2021.
  • – Ironwood generated $79.2 million in cash from operations in the fourth quarter of 2022, compared to $64.6 million in cash from operations in the fourth quarter of 2021.

Macquarie Global Infrastructure Total Return Fund Inc. CUSIP #: 55608D101

Retrieved on: 
Friday, January 27, 2023
Professional Services, Finance, Macquarie Group, Investment, MGL, Risk, Commonwealth, Fund, Policy, NAV, Deposit Insurance and Credit Guarantee Corporation, Calendar, Derivative, Capital gain, Life insurance, Cryptocurrency

The distribution rate should not be considered the dividend yield or total return on an investment in the Fund.

Key Points: 
  • The distribution rate should not be considered the dividend yield or total return on an investment in the Fund.
  • Certain of the investment techniques that the Fund may employ for hedging or to increase income or total return will expose the Fund to additional risks.
  • The obligations of these other Macquarie Group entities do not represent deposits or other liabilities of Macquarie Bank.
  • Macquarie Bank does not guarantee or otherwise provide assurance in respect of the obligations of these other Macquarie Group entities.